Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 4/20 | 0.45 |
| ▸ | GABRD | O14764 | 4/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.45 |
| ▸ | GABRE | P78334 | 4/20 | 0.45 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.45 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.45 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.45 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1473646 | 0.79 | PTPRC (0.46) | MAOBNPC1RAB9ATSHRSMN1; SMN2 | |
| Benzene SCHEMBL28277789 | 0.79 | BACE1 (0.50) | MAOBSMN1; SMN2MEN1KMT2AALDH1A1 | |
| Benzene SCHEMBL28133344 | 0.79 | BACE1 (0.50) | MAOBSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL210321 | 0.79 | BACE1 (0.50) | MAOBSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL29242287 | 0.78 | KMO (0.42) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL1471565 | 0.78 | MAPT (0.46) | MAOBNPC1RAB9ATP53TSHR | |
| SCHEMBL28296080 | 0.77 | BACE1 (0.48) | MAOBSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL3023333 | 0.77 | GABRP (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1471090 | 0.77 | GABRP (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9467973 | 0.75 | HSD17B3 (0.50) | MAOBALDH1A1CYP1A2MAPK1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915304-B2 | Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT | CONGENIA S.R.L. (IT) | 2011-03-29 | — | — | US | disclosed |
| US-7868000-B2 | Aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868000-B2 | Aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-01-11 | — | — | US | disclosed |
| EP-2091531-B1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S R L (IT) | 2010-11-24 | — | — | EP | disclosed |
| US-20100099736-A1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
| EP-2091531-A2 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | Congenia S.r.l. (IT) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008067863-A2 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S.R.L. (IT) | 2008-06-12 | — | — | WO | disclosed |
| US-20070060575-A1 | Aspartyl protease inhibitors | MERCK SHARP & DOHME LLC | 2007-03-15 | — | — | US | disclosed |
| US-20070060575-A1 | Aspartyl protease inhibitors | MERCK SHARP & DOHME LLC | 2007-03-15 | — | — | US | disclosed |
| WO-2006138264-A2 | ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060575-A1 | Aspartyl protease inhibitors | CHRM2, BACE1, CHRM1 | GABRP 2216/4885GABRD 2598/4885GABRA1 2644/4885 |
| US-20100099736-A1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CYC1, MTPN, TXN2 | GABRP 2357/4885GABRD 2550/4885GABRA1 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.